CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income	$ 59,926	$ 21,411	$ 16,617
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	27,067	20,868	15,778
Amortization of debt discount and issuance costs	10,970	7,536	4,248
Stock-based compensation expense	17,007	12,847	10,192
Deferred income taxes, net	(3,992)	(624)	71
Loss on extinguishment of debt		5,650
Other	267	663	(3)
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(21,020)	(7,726)	(6,101)
Royalties and other receivables	128	(104)	7
Unbilled receivables	456	2,146	(2,602)
Inventories	(29,260)	(9,314)	(4,042)
Prepaid expenses and other assets	(4,870)	(595)	(1,769)
Operating lease right of use assets	3,583	(4,662)
Other assets	(281)	(66)
Accounts payable	2,462	662	2,266
Accrued expenses	1,037	13,096	(1,398)
Operating lease liability	(1,964)	5,447
Long-term liabilities	1,109	(19)	(494)
Total cash provided by operating activities	62,625	67,216	32,770
Cash flows from investing activities:
Additions to capitalized software costs	(3,889)	(4,650)	(2,147)
Developed technology intangible asset payment			(1,255)
Acquisition of assets, net of cash acquired	(175,041)	(182,154)
Purchases of property, plant and equipment	(22,455)	(18,504)	(10,635)
Total cash used in investing activities	(201,385)	(205,308)	(14,037)
Cash flows from financing activities:
Proceeds from issuance of senior convertible notes, net of issuance costs		278,466
Proceeds from issuance of common stock, net of issuance costs	297,775	320,713
Exercise of stock options	8,151	1,167	3,418
Repayment of senior convertible notes		(114,989)	(11)
Payment of tax withholding obligation on vesting of restricted stock	(10)	(490)
Total cash provided by financing activities	305,916	484,867	3,407
Effect of exchange rate changes on cash, cash equivalents and restricted cash	12,729	(3,190)	(2,077)
Net increase in cash, cash equivalents and restricted cash	179,885	343,585	20,063
Cash, cash equivalents and restricted cash, beginning of period	537,407	193,822	173,759
Cash, cash equivalents and restricted cash, end of period	717,292	537,407	193,822
Supplemental disclosure of cash flow information:
Income taxes paid	10,279	6,505	4,046
Interest paid	1,066	1,484	2,444
Supplemental disclosure of non-cash investing and financing activities:
Assets acquired under operating leases	3,349	8,663
Fair value of 2,316,229 shares of common stock issued for conversion of convertible notes		198,757
Non-cash effect of adoption of ASU 2016-16			5,609
Property, plant and equipment related to lease incentives			$ 2,270
C Technologies Inc
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition		$ 53,938
ARTeSYN Biosolutions Holdings Ireland Limited
Supplemental disclosure of non-cash investing and financing activities:
Fair value of common stock issued for acquisition	$ 69,422